IPCS 2026

Overview of IPCS

Prostate cancer remains one of the most prevalent malignancies affecting men worldwide, posing significant health, societal, and economic challenges. While early-stage disease is often treatable, advanced and treatment-resistant forms continue to demand innovative therapeutic strategies. With the rapid evolution of molecular diagnostics, precision oncology, immunotherapy, and combination approaches, the landscape of prostate cancer treatment is undergoing a profound transformation. The International Prostate Cancer Symposium (IPCS) brings together leading experts from around the globe to explore and discuss the most promising next-generation treatment modalities, aiming to improve outcomes, extend survival, and enhance quality of life for patients across all disease stages.

The International Prostate Cancer Symposium – IPCS is a specialized event that takes place in the days leading up to the Advanced Prostate Cancer Consensus Conference (APCCC). It serves as a focused meeting point where experts, researchers, clinical specialists, and industry representatives gather to delve deeper into specific topics related to next-generation treatment modalities poised to transform prostate cancer care and shape future consensus treatment guidelines.

IPCS 2026 brings together a truly international audience of leading researchers, clinicians, and industry innovators from across the globe. With participants from major academic centres and pharmaceutical companies, the symposium serves as a dynamic platform for cross-sector dialogue, knowledge exchange, and strategic networking. Designed to foster new collaborations and accelerate translational impact, IPCS is a unique opportunity to connect with global thought leaders shaping the future of prostate cancer research and treatment.

As prostate cancer care enters a new era of precision medicine, IPCS 2026 will serve as a critical meeting point to explore and debate the most promising emerging therapies. From next-generation AR inhibitors and combination regimens to theranostics, antibody-drug conjugates, and immunotherapies, the symposium will spotlight innovative approaches that challenge current standards. By bringing together pioneers in basic, translational, and clinical research, IPCS fosters informed discussion around the clinical value, feasibility, and integration of these advances, paving the way for their transition from experimental strategies to future consensus treatments.

We kindly invite you to save the date for the next IPCS, which will take place in Lugano on April 28–29, 2026, just before APCCC 2026.

On behalf of the IPCS Scientific Advisory Board

Prof. Andrea Alimonti  – Director, Institute of Oncology Research (IOR) – Switzerland
Prof. Silke Gillessen – Director, Institute of Oncology of Southern Switzerland (IOSI) – Switzerland
Prof. Jean-Philippe Theurillat  – Institute of Oncology Research (IOR) – Switzerland

This event is organized by the Foundation for the Institute of Oncology Research in collaboration with APC Society.